By Investing.com Staff After-Hours Stock Movers: Relmada Therapeutics (NASDAQ:RLMD) 37% LOWER; announced results of the RELIANCE I study (REL-1017-301), evaluating REL-1017 as an...
Investing.com - Relmada Therapeutics (NASDAQ:RLMD) reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was in line with...
Zoetis Inc (NYSE:ZTS). ZTS posted second-quarter 2021 adjusted earnings of $1.19 per share (excluding one-time items), which were up from the year-ago quarter’s earnings of...
Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but...
1. Aethlon Medical, Inc. (AEMD) Aethlon Medical (NASDAQ:AEMD) has been exploding of late, since the debacle started. This stock has gone, literally, from 76 cents to Monday’s...
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
|Average||13.38 (+213.23% Upside)|
|No. of Analysts||4|